A Glimpse Into The Expert Outlook On Exact Sciences Through 5 Analysts
Portfolio Pulse from Benzinga Insights
Exact Sciences (NASDAQ:EXAS) has been rated by 5 analysts in the past three months, with 3 bullish and 2 somewhat bullish ratings. The average 12-month price target is $88.2, with a high of $91.00 and a low of $80.00, marking a 7.16% decrease in the average target. Analysts from Benchmark, Guggenheim, Goldman Sachs, and Piper Sandler have provided recent evaluations, with some lowering their price targets. Exact Sciences, known for its cancer screening tests, shows a positive revenue trend but lags in growth rate compared to peers, has a strong net margin, but faces challenges in ROE and excels in ROA. The company maintains a prudent debt management with a debt-to-equity ratio of 0.82.
January 02, 2024 | 8:00 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Exact Sciences has received mixed analyst ratings with a downward revision in the average price target, indicating a cautious outlook from the financial experts.
The mixed analyst ratings and the decrease in the average price target suggest a cautious but not overtly negative sentiment. This could lead to a neutral short-term impact on the stock as investors digest the varied opinions and revised targets. The company's strong net margin and ROA are positive, but the challenges in ROE and lower growth rate compared to peers may temper investor enthusiasm.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100